CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
IBL-302 is a novel small molecule therapy targeting breast cancer by inhibiting both the PI3K and PIM pathways. This dual action aims to induce cancer cell death, offering a potential new treatment option for patients who do not respond to existing therapies.
Breast cancer is already a leading cause of death among women and most common form of cancer among European women with almost 500,000 cases in 2012 and over 1.7 million new cases globally.
However, despite good progress in treatment options over the past decade, including some progress with immunotherapies, the war is far from won, with over 20% not responding to current standard care, and with the incidence of breast cancer set to rise by a massive 50% by 2030.
There is now an urgent need for n…
INFLECTION BIOSCIENCES LIMITED
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
